세계의 주기성 월경 과다 시장 보고서(2025년)
Cyclic Heavy Menstrual Bleeding Global Market Report 2025
상품코드 : 1824634
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,516,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,419,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,322,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

주기성 월경 과다 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년에는 CAGR 6.2%를 나타내 581억 달러로 성장할 전망입니다. 예측 기간의 성장은 여성 인구 증가, 비만 유병률 증가, 건강 관리 접근성 증가, 바이오시밀러 인기 증가, 예방 치료에 대한 수요 증가로 인한 것으로 보입니다. 예측 기간의 주요 동향으로는 의료 진보, 낮은 침습 수술, 영양학적 접근, 환경 친화적인 생리 용품 등이 있습니다.

향후 5년간의 성장률 6.2%라는 예측은 전회 예측으로부터 0.1%의 소폭의 감소를 반영하고 있습니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향 때문입니다. 관세의 부과는 핀란드와 네덜란드에서 수입되는 특수한 자궁내막 소작장치와 호르몬성 IUD에 대한 접근을 제한하고, 부인과 계통의 고통을 늘리고 여성의 의료비를 증가시킬 수 있기 때문에 미국에 큰 과제가 될 수 있습니다. 또한 상호관세와 무역의 긴장과 한계 증가로 인한 세계경제와 무역에 대한 악영향으로 인해 그 영향이 더욱 광범위해질 것으로 보입니다.

자궁근종과 폴립의 이환율 상승은 당분간의 주기성 월경 과다 시장 확대의 카탈리스트가 될 것으로 예측됩니다. 자궁 근종과 자궁 폴립은 여성의 자궁 내에서 발생할 수 있는 일반적인 비암성 증식입니다. 이 질병의 치료는 출혈량을 줄이고, 월경주기를 정돈하고, 합병증을 예방하고, 월경 장애와 싸우는 개인의 정신적 행복을 향상시키는 데 매우 중요한 역할을 합니다. 예를 들어, 2022년 3월 기준 스위스 학술지 'Frontiers'에 게재된 데이터는 미국에서 무작위로 선정된 35세에서 49세의 여성 1,346명을 대상으로 실시된 조사 결과를 보고했습니다. 이 연구는 자기 신고에 의존한 것으로, 아프리카계 미국인 여성에서는 35세까지 자궁근종의 발생률이 60%에 달하고, 50세까지 80% 이상으로 증가하는 것이 밝혀졌습니다. 대조적으로, 동일한 조사의 백인 여성에서 35세까지의 자궁근종 발생률은 40%를 나타내 50세까지 70% 가까이 상승했습니다. 따라서 자궁 근종과 폴립의 유병률 증가는 주기성 월경 과다 시장 성장의 원동력이 되었습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

KTH
영문 목차

영문목차

Cyclic heavy menstrual bleeding is a medical condition characterized by abnormally heavy and prolonged menstrual periods that occur regularly on a monthly cycle. It can result from a variety of factors, including hormonal imbalances, uterine fibroids, polyps, adenomyosis (a condition in which the uterine lining grows into the muscular wall of the uterus), certain medications, or underlying medical conditions. The treatment for this condition involves employing a range of medical strategies and interventions to effectively manage its symptoms and associated complications.

The primary types of cyclic heavy menstrual bleeding include polymenorrhea, oligomenorrhea, and metrorrhagia. Polymenorrhea is a medical term used to describe menstrual cycle irregularities where a woman experiences menstrual periods more frequently than the typical cycle length of approximately 21 to 35 days. Treatment options encompass medications, hormonal therapy, and surgical procedures, with various methods of administration such as oral and parenteral. These treatments are utilized by diverse end-users, including hospitals, home-based care, specialty clinics, and others.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The cyclic heavy menstrual bleeding market research report is one of a series of new reports from The Business Research Company that provides cyclic heavy menstrual bleeding market statistics, including cyclic heavy menstrual bleeding industry global market size, regional shares, competitors with a cyclic heavy menstrual bleeding market share, detailed cyclic heavy menstrual bleeding market segments, market trends and opportunities and any further data you may need to thrive in the cyclic heavy menstrual bleeding industry. This cyclic heavy menstrual bleeding market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cyclic heavy menstrual bleeding market size has grown strongly in recent years. It will grow from $42.97 billion in 2024 to $45.7 billion in 2025 at a compound annual growth rate (CAGR) of 6.3%. The growth in the historic period can be attributed to aging population, raise awareness about menstrual health, rising disposable incomes, government initiatives.

The cyclic heavy menstrual bleeding market size is expected to see strong growth in the next few years. It will grow to $58.1 billion in 2029 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to growing female population, rising prevalence of obesity, increasing access to healthcare, growing popularity of biosimilars, increasing demand for preventive treatments. Major trends in the forecast period include medical advancements, minimally invasive procedures, nutritional approaches, eco-friendly menstrual products.

The forecast of 6.2% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may pose a significant challenge for the U.S. by restricting access to specialized endometrial ablation devices and hormonal IUDs imported from Finland and the Netherlands, potentially prolonging gynecological suffering and increasing women's health costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The escalating incidence of uterine fibroids and polyps is anticipated to serve as a catalyst for the expansion of the cyclic heavy menstrual bleeding market in the foreseeable future. Uterine fibroids and uterine polyps are common noncancerous growths that can develop within the uterus (womb) of women. Treatment for these conditions plays a pivotal role in reducing blood loss, regulating the menstrual cycle, preventing complications, and improving the emotional well-being of individuals grappling with menstrual disorders. For instance, as of March 2022, data published in Frontiers, a journal based in Switzerland, reported the results of a survey conducted in the United States among 1,346 randomly selected women aged 35 to 49. The survey, which relied on self-reporting, revealed a 60% incidence of uterine fibroids by age 35 among African-American women, which increased to over 80% by age 50. In contrast, Caucasian women in the same study exhibited an incidence of 40% by age 35, escalating to nearly 70% by age 50. Hence, the increasing prevalence of uterine fibroids and polyps is a driving force behind the growth of the cyclic heavy menstrual bleeding market.

The increasing awareness regarding menstrual health and the implementation of government initiatives are poised to act as driving forces for the growth of the cyclic heavy menstrual bleeding market in the foreseeable future. Menstrual health awareness encompasses the knowledge, understanding, and acknowledgment of various aspects related to the menstrual cycle, reproductive health, and the physical and emotional well-being of individuals experiencing menstruation. It aims to address social taboos, dispel myths and misconceptions surrounding menstruation, and empower individuals to manage their menstrual health confidently, with dignity, and access to essential resources. For instance, as of May 2022, the World Bank, a US-based financial institution, reported that the government of Ghana introduced The GAMA Sanitation and Water Project. This initiative included a comprehensive qualitative study to explore the effects of Menstrual Health Management (MHM) interventions in schools on the educational engagement of adolescent girls. The project involved the construction of sanitation facilities in over 260 schools throughout the Greater Accra Metropolitan Area. These facilities featured separate and secure toilets and changing rooms for girls, equipped with locks on doors, hygienic and safe disposal areas for used sanitary products, and handwashing facilities. Consequently, the rising awareness of menstrual health and government initiatives are key drivers behind the growth of the cyclic heavy menstrual bleeding market.

Major companies in the cyclic heavy menstrual bleeding market are focusing on developing innovative products, such as menstrual health solutions, to support and enhance menstrual well-being. These menstrual health products are designed to manage menstrual flow and maintain hygiene during menstruation, including items like sanitary pads, tampons, and menstrual cups. They provide comfort, convenience, and protection during the menstrual cycle. For example, in August 2022, Looni, a US-based women's health company, introduced its first menstrual health product, the Balance Beam Mood Complex. This daily supplement is designed to support hormone and neurotransmitter balance, helping reduce mood swings and menstrual discomfort. Priced at $39.99 for a 30-day supply, it contains bioavailable vitamins, minerals, nootropics, and adaptogens.

In October 2022, Unified Women's Healthcare, a healthcare company based in the United States specializing in women's healthcare treatment, completed the acquisition of Gennev for an undisclosed sum. This strategic move by Unified Women's Healthcare is aimed at enhancing its women's healthcare portfolio to offer improved healthcare outcomes and a superior patient experience across all stages of a woman's healthcare journey. Gennev, also based in the United States, is a company dedicated to providing feminine care services, offering a range of treatments that empower women to actively manage their health during and after menopause. This acquisition serves as a pivotal step in strengthening women's healthcare services.

Major companies operating in the cyclic heavy menstrual bleeding market are Pfizer Inc., Merck and Co. Inc., Novartis AG, Abbott Laboratories, GlaxoSmithKline PLC, Medtronic PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Reckitt Benckiser Group PLC, Teva Pharmaceutical Industries Ltd., Mylan N.V., Bausch Health Companies Inc., Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Perrigo Company PLC, Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Limited, Cipla Limited, Ferring B.V., Amneal Pharmaceuticals LLC, Zydus Lifesciences Ltd., Lupin Limited, Torrent Pharmaceuticals Ltd.

North America was the largest region in the cyclic menstrual bleeding market in 2024. The regions covered in cyclic heavy menstrual bleeding report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the cyclic heavy menstrual bleeding market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The cyclic heavy menstrual bleeding market consists of revenues earned by entities by provide diagnostic testing, treatment planning and non-hormonal medications. The market value includes the value of related goods sold by the service provider or included within the service offering. The cyclic heavy menstrual bleeding market also includes sales of sanitary products, hormonal contraceptives, tranexamic acid and nonsteroidal anti-inflammatory drugs (NSAIDs). Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Cyclic Heavy Menstrual Bleeding Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cyclic heavy menstrual bleeding market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for cyclic heavy menstrual bleeding ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The cyclic heavy menstrual bleeding market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Cyclic Heavy Menstrual Bleeding Market Characteristics

3. Cyclic Heavy Menstrual Bleeding Market Trends And Strategies

4. Cyclic Heavy Menstrual Bleeding Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Cyclic Heavy Menstrual Bleeding Growth Analysis And Strategic Analysis Framework

6. Cyclic Heavy Menstrual Bleeding Market Segmentation

7. Cyclic Heavy Menstrual Bleeding Market Regional And Country Analysis

8. Asia-Pacific Cyclic Heavy Menstrual Bleeding Market

9. China Cyclic Heavy Menstrual Bleeding Market

10. India Cyclic Heavy Menstrual Bleeding Market

11. Japan Cyclic Heavy Menstrual Bleeding Market

12. Australia Cyclic Heavy Menstrual Bleeding Market

13. Indonesia Cyclic Heavy Menstrual Bleeding Market

14. South Korea Cyclic Heavy Menstrual Bleeding Market

15. Western Europe Cyclic Heavy Menstrual Bleeding Market

16. UK Cyclic Heavy Menstrual Bleeding Market

17. Germany Cyclic Heavy Menstrual Bleeding Market

18. France Cyclic Heavy Menstrual Bleeding Market

19. Italy Cyclic Heavy Menstrual Bleeding Market

20. Spain Cyclic Heavy Menstrual Bleeding Market

21. Eastern Europe Cyclic Heavy Menstrual Bleeding Market

22. Russia Cyclic Heavy Menstrual Bleeding Market

23. North America Cyclic Heavy Menstrual Bleeding Market

24. USA Cyclic Heavy Menstrual Bleeding Market

25. Canada Cyclic Heavy Menstrual Bleeding Market

26. South America Cyclic Heavy Menstrual Bleeding Market

27. Brazil Cyclic Heavy Menstrual Bleeding Market

28. Middle East Cyclic Heavy Menstrual Bleeding Market

29. Africa Cyclic Heavy Menstrual Bleeding Market

30. Cyclic Heavy Menstrual Bleeding Market Competitive Landscape And Company Profiles

31. Cyclic Heavy Menstrual Bleeding Market Other Major And Innovative Companies

32. Global Cyclic Heavy Menstrual Bleeding Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Cyclic Heavy Menstrual Bleeding Market

34. Recent Developments In The Cyclic Heavy Menstrual Bleeding Market

35. Cyclic Heavy Menstrual Bleeding Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기